MSH6 antibody Monoclonal Antibodies Primary antibodies
- Known as:
- MSH6 (anti-) Monoclonal Antibodies Primary antibodies
- Catalog number:
- orb119630
- Product Quantity:
- 100
- Category:
- -
- Supplier:
- Biorb
- Gene target:
- MSH6 antibody Monoclonal Antibodies Primary antibodies
Related genes to: MSH6 antibody Monoclonal Antibodies Primary antibodies
- Gene:
- MSH6 NIH gene
- Name:
- mutS homolog 6
- Previous symbol:
- GTBP
- Synonyms:
- -
- Chromosome:
- 2p16.3
- Locus Type:
- gene with protein product
- Date approved:
- 1995-08-29
- Date modifiied:
- 2019-04-23
Related products to: MSH6 antibody Monoclonal Antibodies Primary antibodies
Related articles to: MSH6 antibody Monoclonal Antibodies Primary antibodies
- Lung cancer remains the leading cause of cancer-related mortality in the United States, characterized by poor overall survival rates (OS), particularly for advanced-stage disease. While smoking is a primary risk factor, other contributors include environmental exposures, genetics, comorbidities, and socioeconomic factors. We included 232 patients with lung cancer (96% NSCLC). Patients were categorized into DNA damage response (DDR)-mutant (DDR, = 67, 29%) and DDR-wild-type (DDR, n = 165, 71%) groups. We evaluated the correlations between individual and socioeconomic factors between DDR and DDR lung cancer patients. Nineteen DDR genes were identified, with 31.3%, 19.4%, 14.9%, 14.9%, 11.9%, 11.9%, 8.9%, and (5.9%) being the most common. The DDR group had a significantly higher median tumor mutational burden (TMB) (12 vs. 9; = 0.006) and a higher prevalence of adenocarcinoma (85.1% vs. 64.8%, = 0.003). Logistic regression identified adenocarcinoma histology (OR = 10.03, = 0.002) and lower area deprivation index (OR = 0.98, = 0.04) as predictors of DDR mutation status. Having advanced stage at diagnosis was associated with, age ( = 0.03), lack of lung cancer screening ( < 0.001), and adenocarcinoma histology ( < 0.001). While median OS was 61 months for the DDR group vs. 44 months for the DDR group ( = 0.654), patients with mutations had significantly shorter survival (13 vs. 67 months; = 0.0008). Population-level factors, including food insecurity (HR = 2.33, = 0.002), lack of insurance (HR = 2.39, = 0.008), and proximity to potential chemical accidents (HR = 1.73, = 0.037), were significant predictors of OS. These findings suggest that DDR lung cancers represent a biologically distinct subgroup characterized by higher tumor mutational burden and enrichment for adenocarcinoma histology; however, DDR mutation status alone was not associated with overall survival. Instead, outcomes appeared to vary by individual DDR gene, with alterations identifying a subgroup with particularly poor survival. In parallel, food insecurity, lack of insurance, and proximity to potential environmental hazards were associated with outcomes, highlighting the need to integrate genomic biomarkers with social and environmental determinants of health. These data suggest the need for future prospective studies incorporating treatment-response data, longitudinal social determinants of health (SDOH) assessment, and environmental exposure measures to define how DDR alterations can guide precision oncology strategies while addressing modifiable barriers to equitable cancer care. - Source: PubMed
Publication date: 2026/08/13
Nanaa AhmadKao JeremyDavis MartinPasquinelli MaryGeise Margaret WrightLiu LiNguyen Ryan Huu-TuanWeinberg Frank - - Source: PubMed
Publication date: 2026/08/25
Moisoiu VladLourman RoxanneSzulzewsky FrankKessler TobiasCollotta GiulioPorro AntonioBertolini AnneSinger FranziskaCimino Patrick JHertler CarolineWick WolfgangReifenberger GuidoHolland Eric CSartori Alessandro AWeller MichaelWirsching Hans-Georg - Sebaceous adenoma is a rare benign sebaceous neoplasm that only exceptionally involves the ocular adnexa. Caruncular lesions are particularly uncommon and often resemble more frequently encountered lesions such as papilloma. Correct diagnosis of these tumours is important because sebaceous neoplasms may be associated with Muir-Torre syndrome (MTS), a hereditary cancer predisposition syndrome within the Lynch syndrome spectrum. Modern pathology reports incorporate mismatch repair (MMR) immunohistochemistry to help identify patients who may require genetic assessment and cancer surveillance. We present the case of an 81-year-old woman who presented with a right caruncular lesion associated with epiphora and mucoid discharge. Clinical examination demonstrated a cream coloured papillomatous lesion that was mobile and not adherent to adjacent structures. The lesion was presumed clinically to represent a benign papilloma and was excised during combined lacrimal surgery. Histopathological examination demonstrated a well-circumscribed lobulated sebaceous proliferation composed predominantly of mature sebocytes with peripheral basaloid germinative cells and no significant atypia, consistent with sebaceous adenoma. Immunohistochemistry demonstrated preserved nuclear expression of MutL Homologue 1 (MLH1), postmeiotic segregation increased 2 (PMS2), MutS homologue 2 (MSH2) and MutS homologue 6 (MSH6), indicating intact MMR function and reducing suspicion for MTS. Sebaceous adenoma should be considered in the differential diagnosis of cream-white papillomatous caruncular lesions. Ophthalmologists should understand the significance of MMR immunohistochemistry, as abnormal results may identify patients requiring genetic referral, whereas preserved expression is generally reassuring and supports a sporadic lesion. Retained nuclear staining for MLH1, PMS2, MSH2 and MSH6 indicated preserved MMR function (MMR proficient; pMMR), which predicts microsatellite stability (MSS). In conjunction with the patient's age and absence of a personal history of malignancy, these findings strongly favoured a sporadic sebaceous adenoma. Although intact MMR expression does not completely exclude MTS, abnormal staining would have prompted consideration of genetic referral and systemic evaluation. Our report expands upon previous literature by providing a practical explanation of MMR immunohistochemistry aimed at ophthalmologists, who may be the first clinicians to recognise sebaceous neoplasia and initiate appropriate MTS screening. - Source: PubMed
Publication date: 2026/07/22
Cheung ImogenCheung David - Deficiency in SWItch/Sucrose Non-FermenTable (SWI/SNF) related barrier-to-autointegration factor (BAF) chromatin remodeling complex subunit ATPase 4 (SMARCA4) drives aggressive behavior across various undifferentiated malignancies. However, its clinicopathological features, prognostic analysis, and molecular significance in undifferentiated digestive system malignancies, clinically rare and poorly characterized entities, remain incompletely elucidated. This study investigated the clinicopathological characteristics and prognostic significance of a retrospective cohort (n = 43). Immunohistochemistry (IHC) identified SMARCA4 deficiency in 30.2% of undifferentiated malignant tumors of the digestive system. Clinically, SMARCA4 deficiency constituted a significant poor-prognosis predictor, correlating with poorer overall survival [OS; hazard ratio (HR) = 3.054, 95% confidence interval (CI) 1.277-7.306, log-rank p = 0.006] and disease-free survival (DFS; HR = 2.717, 95% CI 1.129-6.539, log-rank p = 0.015), independent of assessed lineage markers or microsatellite status. Integrated analysis of The Cancer Genome Atlas (TCGA) data of digestive system malignancies revealed that SMARCA4-mutated tumors exhibited elevated tumor mutational burden (TMB) and distinct co-mutation patterns. Notably, SMARCA4 mutations significantly co-occurred with multiple potentially actionable therapeutic targets, including receptor tyrosine kinases (ERBB2, ERBB3, MET, and RET), DNA damage response genes (BRCA2), and mismatch repair genes (MLH1, MSH2, MSH6). Collectively, our findings identified SMARCA4 deficiency as a predictor of poor prognoses in digestive system malignancies, suggesting a distinct genomic context that may inform therapeutic stratification, including targeted and immunotherapeutic approaches, by focusing on these high-frequency co-mutated targets. © 2026 The Pathological Society of Great Britain and Ireland. - Source: PubMed
Publication date: 2026/08/20
Guo Yun-RanLiu ChangBai XiaoLi Ke-ChenZhao Jia-BaoLin KunZhao Zi-TingLang Ji-XuanLi Xiao-HanWu Qi-JunZhang Chun-Dong - Multilocus inherited neoplasia alleles syndrome (MINAS) can pair a germline pathogenic variant with a pathogenic mismatch-repair (MMR) variant, but current guidelines manage the two inherited pathways separately. - Source: PubMed
Publication date: 2026/08/21
Chen RuiGe ChuangYuan FangFu KaiwenLong XingtaoWu KeWang Lifeng